{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:47:17Z","timestamp":1791582437062,"version":"4.3.4"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic kidney disease (CKD) patients often exhibit a low muscle mass and strength, leading to physical impairment and an increased mortality. Two major signalling pathways control protein synthesis, the insulin-like growth factor-1\/Akt (IGF-1\/Akt) pathway, acting as a positive regulator, and the myostatin (Mstn) pathway, acting as a negative regulator. Mstn, also known as the growth development factor-8 (GDF-8), is a member of the transforming growth factor-\u03b2 superfamily, which is secreted by mature muscle cells. Mstn inhibits satellite muscle cell proliferation and differentiation and induces a proteolytic phenotype of muscle cells by activating the ubiquitin\u2013proteasome system. Recent advances have been made in the comprehension of the Mstn pathway disturbance and its role in muscle wasting during CKD. Most studies report higher Mstn concentrations in CKD and dialysis patients than in healthy subjects. Several factors increase Mstn production in uraemic conditions: low physical activity, chronic or acute inflammation and oxidative stress, uraemic toxins, angiotensin II, metabolic acidosis and glucocorticoids. Mstn seems to be only scarcely removed during haemodialysis or peritoneal dialysis, maybe because of its large molecule size in plasma where it is linked to its prodomain. In dialysis patients, Mstn has been proposed as a biomarker of muscle mass, muscle strength or physical performances, but more studies are needed in this field. This review outlines the interconnection between Mstn activation, muscle dysfunction and CKD. We discuss mechanisms of action and efficacy of pharmacological Mstn pathway inhibition that represents a promising treatment approach of striated muscle dysfunction. Many approaches and molecules are in development but until now, no study has proved a benefit in CKD.<\/jats:p>","DOI":"10.1093\/ndt\/gfaa129","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T19:10:34Z","timestamp":1590693034000},"page":"1986-1993","source":"Crossref","is-referenced-by-count":89,"title":["Myostatin and muscle atrophy during chronic kidney disease"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8344-1300","authenticated-orcid":false,"given":"Stanislas","family":"Bataille","sequence":"first","affiliation":[{"name":"Phocean Nephrology Institute, Clinique Bouchard, ELSAN, Marseille, France"},{"name":"Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Chauveau","sequence":"additional","affiliation":[{"name":"Aurad-Aquitaine, Gradignan, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Fouque","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-B\u00e9nite, Lyon, France"},{"name":"Univ. Lyon, CarMeN lab, INSA-Lyon, INSERM U1060, INRA, Universit\u00e9 Claude Bernard Lyon 1, Villeurbanne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Aparicio","sequence":"additional","affiliation":[{"name":"Aurad-Aquitaine, Gradignan, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Koppe","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-B\u00e9nite, Lyon, France"},{"name":"Univ. Lyon, CarMeN lab, INSA-Lyon, INSERM U1060, INRA, Universit\u00e9 Claude Bernard Lyon 1, Villeurbanne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"2021110917094053800_gfaa129-B1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.kint.2016.02.025","article-title":"Screening for muscle wasting and dysfunction in patients with chronic kidney disease","volume":"90","author":"Carrero","year":"2016","journal-title":"Kidney Int"},{"key":"2021110917094053800_gfaa129-B2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ageing\/afq034","article-title":"Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People","volume":"39","author":"Cruz-Jentoft","year":"2010","journal-title":"Age Ageing"},{"key":"2021110917094053800_gfaa129-B3","doi-asserted-by":"crossref","first-page":"e0176230","DOI":"10.1371\/journal.pone.0176230","article-title":"Sarcopenia in patients with chronic kidney disease not yet on dialysis: analysis of the prevalence and associated factors","volume":"12","author":"de Souza","year":"2017","journal-title":"PLoS One"},{"key":"2021110917094053800_gfaa129-B4","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.clnu.2016.10.016","article-title":"The diagnosis of sarcopenia is mainly driven by muscle mass in hemodialysis patients","volume":"36","author":"Bataille","year":"2017","journal-title":"Clin Nutr"},{"key":"2021110917094053800_gfaa129-B5","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJM199612193352507","article-title":"Mechanisms of muscle wasting\u2014the role of the ubiquitin\u2013proteasome pathway","volume":"335","author":"Mitch","year":"1996","journal-title":"N Engl J Med"},{"key":"2021110917094053800_gfaa129-B6","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1172\/JCI28520","article-title":"Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition","volume":"116","author":"Ohsawa","year":"2006","journal-title":"J Clin Invest"},{"key":"2021110917094053800_gfaa129-B7","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1681\/ASN.2006020131","article-title":"Development of a diagnostic method for detecting increased muscle protein degradation in patients with catabolic conditions","volume":"17","author":"Workeneh","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2021110917094053800_gfaa129-B8","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrneph.2014.112","article-title":"Mechanisms of muscle wasting in chronic kidney disease","volume":"10","author":"Wang","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"2021110917094053800_gfaa129-B9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphys.2018.00235","article-title":"Muscle atrophy induced by mechanical unloading: mechanisms and potential countermeasures","volume":"9","author":"Gao","year":"2018","journal-title":"Front Physiol"},{"key":"2021110917094053800_gfaa129-B10","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00018-013-1513-z","article-title":"FoxO transcription factors: their roles in the maintenance of skeletal muscle homeostasis","volume":"71","author":"Sanchez","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"2021110917094053800_gfaa129-B11","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/s41598-018-20524-9","article-title":"Blocking extracellular activation of myostatin as a strategy for treating muscle wasting","volume":"8","author":"Pirruccello-Straub","year":"2018","journal-title":"Sci Rep"},{"key":"2021110917094053800_gfaa129-B12","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.kint.2018.10.010","article-title":"Emerging role of myostatin and its inhibition in the setting of chronic kidney disease","volume":"95","author":"Verzola","year":"2019","journal-title":"Kidney Int"},{"key":"2021110917094053800_gfaa129-B13","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1111\/febs.12253","article-title":"Mechanisms regulating skeletal muscle growth and atrophy","volume":"280","author":"Schiaffino","year":"2013","journal-title":"FEBS J"},{"key":"2021110917094053800_gfaa129-B14","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1172\/JCI117208","article-title":"Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes","volume":"93","author":"Mitch","year":"1994","journal-title":"J Clin Invest"},{"key":"2021110917094053800_gfaa129-B15","first-page":"3059","article-title":"Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice","volume":"119","author":"Hu","year":"2009","journal-title":"J Clin Invest"},{"key":"2021110917094053800_gfaa129-B16","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.cmet.2013.07.012","article-title":"Stat3 activation links a C\/EBP\u03b4 to myostatin pathway to stimulate loss of muscle mass","volume":"18","author":"Zhang","year":"2013","journal-title":"Cell Metab"},{"key":"2021110917094053800_gfaa129-B17","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1096\/fj.10-176917","article-title":"Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease","volume":"25","author":"Zhang","year":"2011","journal-title":"FASEB J"},{"key":"2021110917094053800_gfaa129-B18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1681\/ASN.2009060571","article-title":"Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy","volume":"21","author":"Zhang","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2021110917094053800_gfaa129-B19","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1371\/journal.pgen.0030079","article-title":"A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs","volume":"3","author":"Mosher","year":"2007","journal-title":"PLoS Genet"},{"key":"2021110917094053800_gfaa129-B20","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa040933","article-title":"Myostatin mutation associated with gross muscle hypertrophy in a child","volume":"350","author":"Schuelke","year":"2004","journal-title":"N Engl J Med"},{"key":"2021110917094053800_gfaa129-B21","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1046\/j.1532-5415.2001.49214.x","article-title":"Polymorphic variation in the human myostatin (GDF-8) gene and association with strength measures in the Women\u2019s Health and Aging Study II cohort","volume":"49","author":"Seibert","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"2021110917094053800_gfaa129-B22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/SPC.0b013e32834bddf9","article-title":"Targeting the myostatin signaling pathway to treat muscle wasting diseases","volume":"5","author":"Han","year":"2011","journal-title":"Curr Opin Support Palliat Care"},{"key":"2021110917094053800_gfaa129-B23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2337\/db08-0943","article-title":"Increased secretion and expression of myostatin in skeletal muscle from extremely obese women","volume":"58","author":"Hittel","year":"2009","journal-title":"Diabetes"},{"key":"2021110917094053800_gfaa129-B24","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1530\/JOE-15-0533","article-title":"Insulin resistance and sarcopenia: mechanistic links between common co-morbidities","volume":"229","author":"Cleasby","year":"2016","journal-title":"J Endocrinol"},{"key":"2021110917094053800_gfaa129-B25","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1053\/j.jrn.2010.05.007","article-title":"Muscle atrophy in chronic kidney disease results from abnormalities in insulin signaling","volume":"20","author":"Price","year":"2010","journal-title":"J Ren Nutr"},{"key":"2021110917094053800_gfaa129-B26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.ki.5001532","article-title":"Work-induced changes in skeletal muscle IGF-1 and myostatin gene expression in uremia","volume":"70","author":"Sun","year":"2006","journal-title":"Kidney Int"},{"key":"2021110917094053800_gfaa129-B27","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/jcsm.12202","article-title":"Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction: Therapy for CKD-associated muscle dysfunction","volume":"8","author":"Enoki","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2021110917094053800_gfaa129-B28","doi-asserted-by":"crossref","first-page":"32084","DOI":"10.1038\/srep32084","article-title":"Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1","volume":"6","author":"Enoki","year":"2016","journal-title":"Sci Rep"},{"key":"2021110917094053800_gfaa129-B29","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1053\/j.ajkd.2006.05.032","article-title":"Hemodialysis modulates gene expression profile in skeletal muscle","volume":"48","author":"Shah","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2021110917094053800_gfaa129-B30","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1523-1755.2005.00409.x","article-title":"Skeletal muscle mRNA for IGF-IEa, IGF-II, and IGF-I receptor is decreased in sedentary chronic hemodialysis patients","volume":"68","author":"Wang","year":"2005","journal-title":"Kidney Int"},{"key":"2021110917094053800_gfaa129-B31","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/ki.2010.494","article-title":"Apoptosis and myostatin mRNA are upregulated in the skeletal muscle of patients with chronic kidney disease","volume":"79","author":"Verzola","year":"2011","journal-title":"Kidney Int"},{"key":"2021110917094053800_gfaa129-B32","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.jrn.2006.04.028","article-title":"Effect of exercise on mRNA levels for growth factors in skeletal muscle of hemodialysis patients","volume":"16","author":"Kopple","year":"2006","journal-title":"J Ren Nutr"},{"key":"2021110917094053800_gfaa129-B33","doi-asserted-by":"crossref","first-page":"e0141035","DOI":"10.1371\/journal.pone.0141035","article-title":"Relationship between blood myostatin levels and kidney function: Shimane CoHRE study","volume":"10","author":"Yano","year":"2015","journal-title":"PLoS One"},{"key":"2021110917094053800_gfaa129-B34","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1093\/ndt\/gfq159","article-title":"Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA","volume":"25","author":"Yilmaz","year":"2010","journal-title":"A novel pathophysiological pathway? Nephrol Dial Transplant"},{"key":"2021110917094053800_gfaa129-B35","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1159\/000489911","article-title":"Serum Fas ligand, serum myostatin and urine TGF-\u03b21 are elevated in autosomal dominant polycystic kidney disease patients with impaired and preserved renal function","volume":"43","author":"Raptis","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"2021110917094053800_gfaa129-B36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.eurger.2015.11.002","article-title":"Critical analytical evaluation of promising markers for sarcopenia","volume":"7","author":"Cavalier","year":"2016","journal-title":"Eur Geriatr Med"},{"key":"2021110917094053800_gfaa129-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/7635459","article-title":"Modulation of myostatin\/hepatocyte growth factor balance by different hemodialysis modalities","volume":"2017","author":"Esposito","year":"2017","journal-title":"BioMed Res Int"},{"key":"2021110917094053800_gfaa129-B38","doi-asserted-by":"crossref","first-page":"809","DOI":"10.4103\/1319-2442.239648","article-title":"Evaluation of the relationship between muscle mass and serum myostatin levels in chronic hemodialysis patients","volume":"29","author":"Koyun","year":"2018","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"2021110917094053800_gfaa129-B39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.23876\/j.krcp.19.019","article-title":"Serum myostatin levels are associated with abdominal aortic calcification in dialysis patients","volume":"38","author":"Lee","year":"2019","journal-title":"Kidney Res Clin Pract"},{"key":"2021110917094053800_gfaa129-B40","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1365-2265.2011.04120.x","article-title":"Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis","volume":"75","author":"Han","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021110917094053800_gfaa129-B41","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1053\/j.jrn.2018.11.010","article-title":"Myostatin and insulin-like growth factor 1 are biomarkers of muscle strength, muscle mass, and mortality in patients on hemodialysis","volume":"29","author":"Delanaye","year":"2019","journal-title":"J Ren Nutr"},{"key":"2021110917094053800_gfaa129-B42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00223-016-0118-6","article-title":"Factors associated with the serum myostatin level in patients undergoing peritoneal dialysis: potential effects of skeletal muscle mass and vitamin D receptor activator use","volume":"99","author":"Yamada","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"2021110917094053800_gfaa129-B43","doi-asserted-by":"crossref","first-page":"18265","DOI":"10.1038\/s41598-019-54404-7","article-title":"Randomised trial on clinical performances and biocompatibility of four high-flux hemodialyzers in two mode treatments: hemodialysis vs post dilution hemodiafiltration","volume":"9","author":"Morena","year":"2019","journal-title":"Sci Rep"},{"key":"2021110917094053800_gfaa129-B44","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfz106.FP418","article-title":"Muscle mass and plasma myostatin after exercise training: a substudy of Renal Exercise (RENEXC)\u2014a randomized controlled trial","author":"Zhou","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2021110917094053800_gfaa129-B45","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1210\/en.2010-0868","article-title":"Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine","volume":"152","author":"Hansen","year":"2011","journal-title":"Endocrinology"},{"key":"2021110917094053800_gfaa129-B46","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2215\/CJN.10511110","article-title":"Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survival","volume":"6","author":"Miyamoto","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021110917094053800_gfaa129-B47","doi-asserted-by":"crossref","first-page":"18117","DOI":"10.1073\/pnas.0505996102","article-title":"Regulation of muscle growth by multiple ligands signaling through activin type II receptors","volume":"102","author":"Lee","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021110917094053800_gfaa129-B48","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/ndt\/gfw472","article-title":"FSTL3 is increased in renal dysfunction","volume":"32","author":"Kralisch","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2021110917094053800_gfaa129-B49","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature01154","article-title":"Functional improvement of dystrophic muscle by myostatin blockade","volume":"420","author":"Bogdanovich","year":"2002","journal-title":"Nature"},{"key":"2021110917094053800_gfaa129-B50","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/gerona\/glt170","article-title":"Propeptide-mediated inhibition of myostatin increases muscle mass through inhibiting proteolytic pathways in aged mice","volume":"69","author":"Collins-Hooper","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2021110917094053800_gfaa129-B51","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mus.25268","article-title":"Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial","volume":"55","author":"Campbell","year":"2017","journal-title":"Muscle Nerve"},{"key":"2021110917094053800_gfaa129-B52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13395-015-0060-8","article-title":"Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice","volume":"5","author":"Latres","year":"2015","journal-title":"Skelet Muscle"},{"key":"2021110917094053800_gfaa129-B53","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1073\/pnas.1525795113","article-title":"Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice","volume":"113","author":"Camporez","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021110917094053800_gfaa129-B54","doi-asserted-by":"crossref","first-page":"14000","DOI":"10.1038\/s41598-017-13912-0","article-title":"Pharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke","volume":"7","author":"Desgeorges","year":"2017","journal-title":"Sci Rep"},{"key":"2021110917094053800_gfaa129-B55","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/MCB.01307-13","article-title":"An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy","volume":"34","author":"Lach-Trifilieff","year":"2014","journal-title":"Mol Cell Biol"},{"key":"2021110917094053800_gfaa129-B56","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3177\/jnsv.63.244","article-title":"Co-administration of myostatin-targeting siRNA and ActRIIB-Fc fusion protein increases masseter muscle mass and fiber size","volume":"63","author":"Bayarsaikhan","year":"2017","journal-title":"J Nutr Sci Vitaminol"},{"key":"2021110917094053800_gfaa129-B57","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","article-title":"Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial","volume":"3","author":"Becker","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2021110917094053800_gfaa129-B58","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jgs.14927","article-title":"Treatment of sarcopenia with bimagrumab: results from a phase II, randomized, controlled, proof-of-concept study","volume":"65","author":"Rooks","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"2021110917094053800_gfaa129-B59","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIRCULATIONAHA.109.872200","article-title":"Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury","volume":"120","author":"Oshima","year":"2009","journal-title":"Circulation"},{"key":"2021110917094053800_gfaa129-B60","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1474-9726.2009.00508.x","article-title":"Effects of myostatin deletion in aging mice","volume":"8","author":"Morissette","year":"2009","journal-title":"Aging Cell"},{"key":"2021110917094053800_gfaa129-B61","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1681\/ASN.2006070794","article-title":"Exercise in maintenance hemodialysis patients induces transcriptional changes in genes favoring anabolic muscle","volume":"18","author":"Kopple","year":"2007","journal-title":"J Am Soc Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/36\/11\/1986\/41116502\/gfaa129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/36\/11\/1986\/41116502\/gfaa129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T18:55:12Z","timestamp":1636484112000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/36\/11\/1986\/5911292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":61,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,9,24]]},"published-print":{"date-parts":[[2021,11,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaa129","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11]]},"published":{"date-parts":[[2020,9,24]]}}}